Is multiple sclerosis a mitochondrial disease?

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 1, 2010, Pages 66-79

  Mao, Peizhong ^a   Reddy, P Hemachandra ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Experimental autoimmune encephalomyelitis; Gender difference; Mitochondria; Multiple sclerosis; Myelin; Neuroprotection; NO; Oxidative stress

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM); BETA1A INTERFERON; CILIARY NEUROTROPHIC FACTOR; DOXYCYCLINE; FIBROBLAST GROWTH FACTOR; FLECAINIDE; GINKGO BILOBA EXTRACT; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON; LYMPHOTOXIN; MITOCHONDRIAL DNA; MITOXANTRONE; MYELIN; NATALIZUMAB; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGEN OXIDE; PEROXYNITRITE; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEASOME; PROTEINASE; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; TETRODOTOXIN; UBIQUITIN; UNINDEXED DRUG;

ABSENCE OF SIDE EFFECTS; ALLERGIC ENCEPHALOMYELITIS; ALTERNATIVE MEDICINE; AUTOPHAGY; CELL ACTIVATION; CLINICAL TRIAL; CYTOKINE RELEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOMODULATION; MICROGLIA; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SEX DIFFERENCE; VIRUS INFECTION;

ANIMALS; HUMANS; MITOCHONDRIAL DISEASES; MODELS, BIOLOGICAL; MULTIPLE SCLEROSIS; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 71849083196     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2009.07.002     Document Type: Review

References (209)

1. Anderson D.W., Ellenberg J.H., Leventhal C.M., Reingold S.C., Rodriguez M., and Silberberg D.H. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31 (1992) 333-336
2. Keegan B.M., and Noseworthy J.H. Multiple sclerosis. Annu. Rev. Med. 53 (2002) 285-302
3. Murray T.J. Diagnosis and treatment of multiple sclerosis. BMJ 332 (2006) 525-527
4. Rogers J.M., and Panegyres P.K. Cognitive impairment in multiple sclerosis: evidence-based analysis and recommendations. J. Clin. Neurosci. 14 (2007) 919-927
5. Murray T.J. The history of multiple sclerosis: the changing frame of the disease over the centuries. J. Neurol. Sci. 277 Suppl. 1 (2009) S3-S8
6. Wallin M.T., Wilken J.A., Turner A.P., Williams R.M., and Kane R. Depression and multiple sclerosis: review of a lethal combination. J. Rehabil. Res. Dev. 43 (2006) 45-62
7. Gilgun-Sherki Y., Melamed E., and Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 251 (2004) 261-268
8. Kleinschnitz C., Meuth S.G., and Wiendl H. The trials and errors in MS therapy. Int. MS J. 15 (2008) 79-90
9. Pirko I., Lucchinetti C.F., Sriram S., and Bakshi R. Gray matter involvement in multiple sclerosis. Neurology 68 (2007) 634-642
10. Chard D., and Miller D. Grey matter pathology in clinically early multiple sclerosis: evidence from magnetic resonance imaging. J. Neurol. Sci. 282 1-2 (2009) 5-11
11. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120 Pt. 5 (1997) 865-916
12. Trapp B.D., and Stys P.K. Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8 (2009) 280-291
13. van der Valk P., and Amor S. Preactive lesions in multiple sclerosis. Curr. Opin. Neurol. 22 (2009) 207-213
14. International Multiple Sclerosis Genetics Consortium, Hafler D.A., Compston A., Sawcer S., Lander E.S., Daly M.J., De Jager P.L., de Bakker P.I., Gabriel S.B., Mirel D.B., Ivinson A.J., Pericak-Vance M.A., Gregory S.G., Rioux J.D., McCauley J.L., Haines J.L., Barcellos L.F., Cree B., Oksenberg J.R., and Hauser S.L. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357 (2007) 851-862
15. Comabella M., Craig D.W., Camina-Tato M., Morcillo C., Lopez C., Navarro A., Rio J., BiomarkerMS Study Group, Montalban X., and Martin R. Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. PLoS ONE 3 (2008) e3490
16. Gregory S.G., Schmidt S., Seth P., Oksenberg J.R., Hart J., Prokop A., Caillier S.J., Ban M., Goris A., Barcellos L.F., Lincoln R., McCauley J.L., Sawcer S.J., Compston D.A., Dubois B., Hauser S.L., Garcia-Blanco M.A., Pericak-Vance M.A., Haines J.L., and Multiple Sclerosis Genetics Group. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39 (2007) 1083-1091
17. Maier L.M., Lowe C.E., Cooper J., Downes K., Anderson D.E., Severson C., Clark P.M., Healy B., Walker N., Aubin C., Oksenberg J.R., Hauser S.L., Compston A., Sawcer S., International Multiple Sclerosis Genetics Consortium, De Jager P.L., Wicker L.S., Todd J.A., and Hafler D.A. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet. 5 (2009) e1000322
18. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., Abad-Grau M.M., Arnal C., Delgado C., Lucas M., Izquierdo G., and Matesanz F. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PLoS ONE 4 (2009) e4137
19. Svejgaard A. The immunogenetics of multiple sclerosis. Immunogenetics 60 (2008) 275-286
20. Baranzini S.E., Galwey N.W., Wang J., Khankhanian P., Lindberg R., Pelletier D., Wu W., Uitdehaag B.M., Kappos L., GeneMSA Consortium, Polman C.H., Matthews P.M., Hauser S.L., Gibson R.A., Oksenberg J.R., and Barnes M.R. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum. Mol. Genet. 18 (2009) 2078-2090
21. Oksenberg J.R., and Barcellos L.F. The complex genetic aetiology of multiple sclerosis. J. Neurovirol. 6 Suppl. 2 (2000) S10-S14
22. Oksenberg J.R., Baranzini S.E., Sawcer S., and Hauser S.L. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat. Rev. Genet. 9 (2008) 516-526
23. Vyshkina T., Leist T.P., Shugart Y.Y., and Kalman B. CD45 (PTPRC) as a candidate gene in multiple sclerosis. Mult. Scler. 10 (2004) 614-617
24. Ascherio A. Epstein-Barr virus in the development of multiple sclerosis. Expert Rev. Neurother. 8 (2008) 331-333
25. Lunemann J.D., Kamradt T., Martin R., and Munz C. Epstein-Barr virus: environmental trigger of multiple sclerosis?. J. Virol. 81 (2007) 6777-6784
26. Jilek S., Schluep M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G., and Du Pasquier R.A. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131 (2008) 1712-1721
27. Ramagopalan S.V., Valdar W., Dyment D.A., DeLuca G.C., Yee I.M., Giovannoni G., Ebers G.C., Sadovnick A.D., and Canadian Collaborative Study Group. Association of infectious mononucleosis with multiple sclerosis. a population-based study. Neuroepidemiology 32 (2009) 257-262
28. Serafini B., Rosicarelli B., Franciotta D., Magliozzi R., Reynolds R., Cinque P., Andreoni L., Trivedi P., Salvetti M., Faggioni A., and Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204 (2007) 2899-2912
29. Arbour N., Day R., Newcombe J., and Talbot P.J. Neuroinvasion by human respiratory coronaviruses. J. Virol. 74 (2000) 8913-8921
30. St-Jean J.R., Jacomy H., Desforges M., Vabret A., Freymuth F., and Talbot P.J. Human respiratory coronavirus OC43: genetic stability and neuroinvasion. J. Virol. 78 (2004) 8824-8834
31. Tong T.R. Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections. Infect. Disord. Drug Targets 9 (2009) 223-245
32. Miller S.D., Katz-Levy Y., Neville K.L., and Vanderlugt C.L. Virus-induced autoimmunity: epitope spreading to myelin autoepitopes in Theiler's virus infection of the central nervous system. Adv. Virus Res. 56 (2001) 199-217
33. Orton S.M., Herrera B.M., Yee I.M., Valdar W., Ramagopalan S.V., Sadovnick A.D., Ebers G.C., and Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol. 5 (2006) 932-936
34. Wolinsky J.S., Shochat T., Weiss S., Ladkani D., and for the PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J. Neurol. Sci. (2009)
35. Nicot A. Gender and sex hormones in multiple sclerosis pathology and therapy. Front. Biosci. 14 (2009) 4477-4515
36. Offner H., and Polanczyk M. A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis. Ann. N. Y. Acad. Sci. 1089 (2006) 343-372
37. Voumvourakis K.I., Tsiodras S., Kitsos D.K., and Stamboulis E. Gender hormones: role in the pathogenesis of central nervous system disease and demyelination. Curr. Neurovasc. Res. 5 (2008) 224-235
38. Bebo Jr. B.F., Dehghani B., Foster S., Kurniawan A., Lopez F.J., and Sherman L.S. Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis. Glia 57 (2009) 777-790
39. Liu M., Hurn P.D., Roselli C.E., and Alkayed N.J. Role of P450 aromatase in sex-specific astrocytic cell death. J. Cereb. Blood Flow Metab. 27 (2007) 135-141
40. Liu M., Oyarzabal E.A., Yang R., Murphy S.J., and Hurn P.D. A novel method for assessing sex-specific and genotype-specific response to injury in astrocyte culture. J. Neurosci. Methods 171 (2008) 214-217
41. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci. 22 (2001) 117-139
42. Sotgiu S., Pugliatti M., Sotgiu A., Sanna A., and Rosati G. Does the "hygiene hypothesis" provide an explanation for the high prevalence of multiple sclerosis in Sardinia?. Autoimmunity 36 (2003) 257-260
43. Freedman D.M., Dosemeci M., and Alavanja M.C. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup. Environ. Med. 57 (2000) 418-421
44. Noseworthy J.H., Lucchinetti C., Rodriguez M., and Weinshenker B.G. Multiple sclerosis. N. Engl. J. Med. 343 (2000) 938-952
45. Compston A. 'The marvellous harmony of the nervous parts': the origins of multiple sclerosis. Clin. Med. 4 (2004) 346-354
46. Frohman E.M., Racke M.K., and Raine C.S. Multiple sclerosis-the plaque and its pathogenesis. N. Engl. J. Med. 354 (2006) 942-955
47. Dutta R., and Trapp B.D. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68 (2007) S22-S31 discussion S43-54
48. Prod'homme T., and Zamvil S.S. Bench to bedside: tempering antigen-presenting cells in multiple sclerosis. Nat. Med. 14 (2008) 614-615
49. Krishnamoorthy G., Saxena A., Mars L.T., Domingues H.S., Mentele R., Ben-Nun A., Lassmann H., Dornmair K., Kurschus F.C., Liblau R.S., and Wekerle H. Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis. Nat. Med. 15 (2009) 626-632
50. De Groot C.J., Bergers E., Kamphorst W., Ravid R., Polman C.H., Barkhof F., and van der Valk P. Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p)reactive lesions. Brain 124 (2001) 1635-1645
51. Filippi M., and Rocca M.A. MRI aspects of the "inflammatory phase" of multiple sclerosis. Neurol. Sci. 24 Suppl. 5 (2003) S275-S278
52. Zeis T., Graumann U., Reynolds R., and Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 131 (2008) 288-303
53. Miller D.H., Thompson A.J., and Filippi M. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol. 250 (2003) 1407-1419
54. Graumann U., Reynolds R., Steck A.J., and Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol. 13 (2003) 554-573
55. Schreibelt G., van Horssen J., van Rossum S., Dijkstra C.D., Drukarch B., and de Vries H.E. Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology. Brain Res. Rev. 56 (2007) 322-330
56. Mahad D., Lassmann H., and Turnbull D. Review: mitochondria and disease progression in multiple sclerosis. Neuropathol. Appl. Neurobiol. 34 (2008) 577-589
57. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., and Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 59 (2006) 478-489
58. Franklin R.J., and Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat. Rev. Neurosci. 9 (2008) 839-855
59. Smith K.J. Sodium channels and multiple sclerosis: roles in symptom production, damage and therapy. Brain Pathol. 17 (2007) 230-242
60. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
61. Dada L.A., Chandel N.S., Ridge K.M., Pedemonte C., Bertorello A.M., and Sznajder J.I. Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. J. Clin. Invest. 111 (2003) 1057-1064
62. Comellas A.P., Dada L.A., Lecuona E., Pesce L.M., Chandel N.S., Quesada N., Budinger G.R., Strous G.J., Ciechanover A., and Sznajder J.I. Hypoxia-mediated degradation of Na,K-ATPase via mitochondrial reactive oxygen species and the ubiquitin-conjugating system. Circ. Res. 98 (2006) 1314-1322
63. Stys P.K., Waxman S.G., and Ransom B.R. Ionic mechanisms of anoxic injury in mammalian CNS white matter: role of Na+ channels and Na(+)-Ca2+ exchanger. J. Neurosci. 12 (1992) 430-439
64. Hirsch H.E., and Parks M.E. Na+- and K+-dependent adenosine triphosphatase changes in multiple sclerosis plaques. Ann. Neurol. 13 (1983) 658-663
65. Young E.A., Fowler C.D., Kidd G.J., Chang A., Rudick R., Fisher E., and Trapp B.D. Imaging correlates of decreased axonal Na+/K+ ATPase in chronic multiple sclerosis lesions. Ann. Neurol. 63 (2008) 428-435
66. Waxman S.G. Axonal dysfunction in chronic multiple sclerosis: meltdown in the membrane. Ann. Neurol. 63 (2008) 411-413
67. Franklin R.J., and Kotter M.R. The biology of CNS remyelination: the key to therapeutic advances. J. Neurol. 255 Suppl. 1 (2008) 19-25
68. Neumann H., Kotter M.R., and Franklin R.J. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 132 (2009) 288-295
69. Back S.A., Tuohy T.M., Chen H., Wallingford N., Craig A., Struve J., Luo N.L., Banine F., Liu Y., Chang A., Trapp B.D., Bebo Jr. B.F., Rao M.S., and Sherman L.S. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat. Med. 11 (2005) 966-972
70. Shields S.A., Gilson J.M., Blakemore W.F., and Franklin R.J. Remyelination occurs as extensively but more slowly in old rats compared to young rats following gliotoxin-induced CNS demyelination. Glia 28 (1999) 77-83
71. Ibanez C., Shields S.A., El-Etr M., Baulieu E.E., Schumacher M., and Franklin R.J. Systemic progesterone administration results in a partial reversal of the age-associated decline in CNS remyelination following toxin-induced demyelination in male rats. Neuropathol. Appl. Neurobiol. 30 (2004) 80-89
72. Eskelinen E.L., and Saftig P. Autophagy: a lysosomal degradation pathway with a central role in health and disease. Biochim. Biophys. Acta 1793 (2009) 664-673
73. Cherra S.J., and Chu C.T. Autophagy in neuroprotection and neurodegeneration: a question of balance. Future Neurol. 3 (2008) 309-323
74. Tsujimoto Y., and Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ. 12 Suppl. 2 (2005) 1528-1534
75. Bredesen D.E. Programmed cell death mechanisms in neurological disease. Curr. Mol. Med. 8 (2008) 173-186
76. Chu C.T. Autophagic stress in neuronal injury and disease. J. Neuropathol. Exp. Neurol. 65 (2006) 423-432
77. Li C., Capan E., Zhao Y., Zhao J., Stolz D., Watkins S.C., Jin S., and Lu B. Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death. J. Immunol. 177 (2006) 5163-5168
78. Lu B., Capan E., and Li C. Autophagy induction and autophagic cell death in effector T cells. Autophagy 3 (2007) 158-159
79. Alirezaei M., Fox H.S., Flynn C.T., Moore C.S., Hebb A.L., Frausto R.F., Bhan V., Kiosses W.B., Whitton J.L., Robertson G.S., and Crocker S.J. Elevated ATG5 expression in autoimmune demyelination and multiple sclerosis. Autophagy 5 (2009) 152-158
80. Ciechanover A., and Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40 (2003) 427-446
81. Nath D., and Shadan S. The ubiquitin system. Nature 458 (2009) 421
82. Ciehanover A., Hod Y., and Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem. Biophys. Res. Commun. 81 (1978) 1100-1105
83. Pickart C.M. Back to the future with ubiquitin. Cell 116 (2004) 181-190
84. Park S., Roelofs J., Kim W., Robert J., Schmidt M., Gygi S.P., and Finley D. Hexameric assembly of the proteasomal ATPases is templated through their C termini. Nature 459 (2009) 866-870
85. Roelofs J., Park S., Haas W., Tian G., McAllister F.E., Huo Y., Lee B.H., Zhang F., Shi Y., Gygi S.P., and Finley D. Chaperone-mediated pathway of proteasome regulatory particle assembly. Nature 459 (2009) 861-865
86. Vanderlugt C.L., Rahbe S.M., Elliott P.J., Dal Canto M.C., and Miller S.D. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J. Autoimmun. 14 (2000) 205-211
87. Ciechanover A., and Schwartz A.L. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim. Biophys. Acta 1695 (2004) 3-17
88. Shiryaev S.A., Savinov A.Y., Cieplak P., Ratnikov B.I., Motamedchaboki K., Smith J.W., and Strongin A.Y. Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS ONE 4 (2009) e4952
89. Luo W., Wang Y., and Reiser G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56 (2007) 331-345
90. Noorbakhsh F., Tsutsui S., Vergnolle N., Boven L.A., Shariat N., Vodjgani M., Warren K.G., Andrade-Gordon P., Hollenberg M.D., and Power C. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203 (2006) 425-435
91. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., and Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 324 (1986) 258-260
92. Greer J.M., Kuchroo V.K., Sobel R.A., and Lees M.B. Identification and characterization of a second encephalitogenic determinant of myelin proteolipid protein (residues 178-191) for SJL mice. J. Immunol. 149 (1992) 783-788
93. Mendel I., Kerlero de Rosbo N., and Ben-Nun A. A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur. J. Immunol. 25 (1995) 1951-1959
94. Gold R., Linington C., and Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129 (2006) 1953-1971
95. Hohlfeld R., and Wekerle H. Immunological update on multiple sclerosis. Curr. Opin. Neurol. 14 (2001) 299-304
96. Furlan R., Cuomo C., and Martino G. Animal models of multiple sclerosis. Methods Mol. Biol. 549 (2009) 157-173
97. 't Hart B.A., Laman J.D., Bauer J., Blezer E., van Kooyk Y., and Hintzen R.Q. Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol. 3 (2004) 588-597
98. Merkler D., Schmelting B., Czeh B., Fuchs E., Stadelmann C., and Bruck W. Myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis in the common marmoset reflects the immunopathology of pattern II multiple sclerosis lesions. Mult. Scler. 12 (2006) 369-374
99. 't Hart B.A., and Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J. Neuropathol. Exp. Neurol. 68 (2009) 341-355
100. Kornek B., Storch M.K., Weissert R., Wallstroem E., Stefferl A., Olsson T., Linington C., Schmidbauer M., and Lassmann H. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am. J. Pathol. 157 (2000) 267-276
101. Wujek J.R., Bjartmar C., Richer E., Ransohoff R.M., Yu M., Tuohy V.K., and Trapp B.D. Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J. Neuropathol. Exp. Neurol. 61 (2002) 23-32
102. Kaneko S., Wang J., Kaneko M., Yiu G., Hurrell J.M., Chitnis T., Khoury S.J., and He Z. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J. Neurosci. 26 (2006) 9794-9804
103. Steinman L., and Zamvil S.S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60 (2006) 12-21
104. Mitrovic B., Parkinson J., and Merrill J.E. An in vitro model of oligodendrocyte destruction by nitric oxide and its relevance to multiple sclerosis. Methods 10 (1996) 501-513
105. Lehnardt S., Massillon L., Follett P., Jensen F.E., Ratan R., Rosenberg P.A., Volpe J.J., and Vartanian T. Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8514-8519
106. Ferguson B., Matyszak M.K., Esiri M.M., and Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 120 Pt 3 (1997) 393-399
107. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., and Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998) 278-285
108. Bjartmar C., and Trapp B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14 (2001) 271-278
109. Forte M., Gold B.G., Marracci G., Chaudhary P., Basso E., Johnsen D., Yu X., Fowlkes J., Rahder M., Stem K., Bernardi P., and Bourdette D. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 7558-7563
110. Trapp B.D., and Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 31 (2008) 247-269
111. Bjartmar C., Kinkel R.P., Kidd G., Rudick R.A., and Trapp B.D. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57 (2001) 1248-1252
112. Filippi M., Bozzali M., Rovaris M., Gonen O., Kesavadas C., Ghezzi A., Martinelli V., Grossman R.I., Scotti G., Comi G., and Falini A. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 126 (2003) 433-437
113. Bjartmar C., and Trapp B.D. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res. 5 (2003) 157-164
114. DiMauro S., and Schon E.A. Mitochondrial respiratory-chain diseases. N. Engl. J. Med. 348 (2003) 2656-2668
115. Reddy P.H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol. 2006 (2006) 31372
116. Reddy P.H. Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med. 10 (2008) 291-315
117. Reddy P.H. Mitochondrial dysfunction in aging and Alzheimer's disease: strategies to protect neurons. Antioxid. Redox Signal. 9 (2007) 1647-1658
118. Ghafourifar P., Mousavizadeh K., Parihar M.S., Nazarewicz R.R., Parihar A., and Zenebe W.J. Mitochondria in multiple sclerosis. Front. Biosci. 13 (2008) 3116-3126
119. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., and Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 39 (2007) 44-84
120. Yankovskaya V., Horsefield R., Tornroth S., Luna-Chavez C., Miyoshi H., Leger C., Byrne B., Cecchini G., and Iwata S. Architecture of succinate dehydrogenase and reactive oxygen species generation. Science 299 (2003) 700-704
121. Senoo-Matsuda N., Hartman P.S., Akatsuka A., Yoshimura S., and Ishii N. A complex II defect affects mitochondrial structure, leading to ced-3- and ced-4-dependent apoptosis and aging. J. Biol. Chem. 278 (2003) 22031-22036
122. Schon E.A., and Manfredi G. Neuronal degeneration and mitochondrial dysfunction. J. Clin. Invest. 111 (2003) 303-312
123. Jenner P. Oxidative stress and Parkinson's disease. Handb. Clin. Neurol. 83 (2007) 507-520
124. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
125. Blokhin A., Vyshkina T., Komoly S., and Kalman B. Variations in mitochondrial DNA copy numbers in MS brains. J. Mol. Neurosci. 35 (2008) 283-287
126. Yu X., Koczan D., Sulonen A.M., Akkad D.A., Kroner A., Comabella M., Costa G., Corongiu D., Goertsches R., Camina-Tato M., Thiesen H.J., Nyland H.I., Mork S.J., Montalban X., Rieckmann P., Marrosu M.G., Myhr K.M., Epplen J.T., Saarela J., and Ibrahim S.M. mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS ONE 3 (2008) e1530
127. Ban M., Elson J., Walton A., Turnbull D., Compston A., Chinnery P., and Sawcer S. Investigation of the role of mitochondrial DNA in multiple sclerosis susceptibility. PLoS ONE 3 (2008) e2891
128. Ghabaee M., Omranisikaroudi M., Amrisaroukolaei S., Meysamie A., Sahraian M.A., Bayati A., Sanati M.H., Houshman M., Sadeghian H., and Vajihazaman K. Mitochondrial mutation in Iranian patients with multiple sclerosis, correlation between haplogroups H, A and clinical manifestations. Cell. Mol. Neurobiol. 29 (2009) 341-346
129. Vyshkina T., Banisor I., Shugart Y.Y., Leist T.P., and Kalman B. Genetic variants of complex I in multiple sclerosis. J. Neurol. Sci. 228 (2005) 55-64
130. Vogler S., Goedde R., Miterski B., Gold R., Kroner A., Koczan D., Zettl U.K., Rieckmann P., Epplen J.T., and Ibrahim S.M. Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J. Mol. Med. 83 (2005) 806-811
131. Vyshkina T., Sylvester A., Sadiq S., Bonilla E., Canter J.A., Perl A., and Kalman B. Association of common mitochondrial DNA variants with multiple sclerosis and systemic lupus erythematosus. Clin. Immunol. 129 (2008) 31-35
132. Harding A.E., Sweeney M.G., Miller D.H., Mumford C.J., Kellar-Wood H., Menard D., McDonald W.I., and Compston D.A. Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain 115 Pt. 4 (1992) 979-989
133. Kalman B., and Alder H. Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis?. Acta Neurol. Scand. 98 (1998) 232-237
134. Mojon D.S., Fujihara K., Hirano M., Miller C., Lincoff N.S., Jacobs L.D., and Greenberg S.J. Leber's hereditary optic neuropathy mitochondrial DNA mutations in familial multiple sclerosis. Graefes Arch. Clin. Exp. Ophthalmol. 237 (1999) 348-350
135. Mihailova S.M., Ivanova M.I., Quin L.M., and Naumova E.J. Mitochondrial DNA variants in Bulgarian patients affected by multiple sclerosis. Eur. J. Neurol. 14 (2007) 44-47
136. Hwang J.M., Chang B.L., and Park S.S. Leber's hereditary optic neuropathy mutations in Korean patients with multiple sclerosis. Ophthalmologica 215 (2001) 398-400
137. Nishimura M., Obayashi H., Ohta M., Uchiyama T., Hao Q., and Saida T. No association of the 11778 mitochondrial DNA mutation and multiple sclerosis in Japan. Neurology 45 (1995) 1333-1334
138. Lu F., Selak M., O'Connor J., Croul S., Lorenzana C., Butunoi C., and Kalman B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 177 (2000) 95-103
139. Kalman B., and Leist T.P. A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular Med. 3 (2003) 147-158
140. Lucchinetti C., Bruck W., Parisi J., Scheithauer B., Rodriguez M., and Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000) 707-717
141. Mahad D.J., Ziabreva I., Campbell G., Lax N., White K., Hanson P.S., Lassmann H., and Turnbull D.M. Mitochondrial changes within axons in multiple sclerosis. Brain 132 (2009) 1161-1174
142. Regenold W.T., Phatak P., Makley M.J., Stone R.D., and Kling M.A. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression. J. Neurol. Sci. 275 (2008) 106-112
143. Kent-Braun J.A., Ng A.V., Castro M., Weiner M.W., Gelinas D., Dudley G.A., and Miller R.G. Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. J. Appl. Physiol. 83 (1997) 1998-2004
144. Bet L., Moggio M., Comi G.P., Mariani C., Prelle A., Checcarelli N., Bordoni A., Bresolin N., Scarpini E., and Scarlato G. Multiple sclerosis and mitochondrial myopathy: an unusual combination of diseases. J. Neurol. 241 (1994) 511-516
145. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., Robbins J., and Molkentin J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
146. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
147. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
148. Simonian N.A., and Coyle J.T. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 83-106
149. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 97 (2006) 1634-1658
150. Bonekamp N.A., Volkl A., Fahimi H.D., and Schrader M. Reactive oxygen species and peroxisomes: struggling for balance. Biofactors (2009)
151. Shokolenko I., Venediktova N., Bochkareva A., Wilson G.L., and Alexeyev M.F. Oxidative stress induces degradation of mitochondrial DNA. Nucleic Acids Res. 37 (2009) 2539-2548
152. Sayre L.M., Perry G., and Smith M.A. Oxidative stress and neurotoxicity. Chem. Res. Toxicol. 21 (2008) 172-188
153. Gray E., Thomas T.L., Betmouni S., Scolding N., and Love S. Elevated myeloperoxidase activity in white matter in multiple sclerosis. Neurosci. Lett. 444 (2008) 195-198
154. Vladimirova O., Lu F.M., Shawver L., and Kalman B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. Inflamm. Res. 48 (1999) 412-416
155. Smith K.J., Kapoor R., and Felts P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 9 (1999) 69-92
156. Bizzozero O.A., DeJesus G., Callahan K., and Pastuszyn A. Elevated protein carbonylation in the brain white matter and gray matter of patients with multiple sclerosis. J. Neurosci. Res. 81 (2005) 687-695
157. Vladimirova O., O'Connor J., Cahill A., Alder H., Butunoi C., and Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult. Scler. 4 (1998) 413-418
158. Koch M., Ramsaransing G.S., Arutjunyan A.V., Stepanov M., Teelken A., Heersema D.J., and De Keyser J. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J. Neurol. 253 (2006) 483-487
159. Calabrese V., Bella R., Testa D., Spadaro F., Scrofani A., Rizza V., and Pennisi G. Increased cerebrospinal fluid and plasma levels of ultraweak chemiluminescence are associated with changes in the thiol pool and lipid-soluble fluorescence in multiple sclerosis: the pathogenic role of oxidative stress. Drugs Exp. Clin. Res. 24 (1998) 125-131
160. van Horssen J., Schreibelt G., Drexhage J., Hazes T., Dijkstra C.D., van der Valk P., and de Vries H.E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med. 45 (2008) 1729-1737
161. Smith K.J., and Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 1 (2002) 232-241
162. Brown G.C., and Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol. 27 (2003) 325-355
163. Sarti P., Arese M., Bacchi A., Barone M.C., Forte E., Mastronicola D., Brunori M., and Giuffre A. Nitric oxide and mitochondrial complex IV. IUBMB Life 55 (2003) 605-611
164. Parihar A., Vaccaro P., and Ghafourifar P. Nitric oxide irreversibly inhibits cytochrome oxidase at low oxygen concentrations: evidence for inverse oxygen concentration-dependent peroxynitrite formation. IUBMB Life 60 (2008) 64-67
165. Hooper D.C., Scott G.S., Zborek A., Mikheeva T., Kean R.B., Koprowski H., and Spitsin S.V. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 14 (2000) 691-698
166. Scott G.S., Cuzzocrea S., Genovese T., Koprowski H., and Hooper D.C. Uric acid protects against secondary damage after spinal cord injury. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 3483-3488
167. Amorini A.M., Petzold A., Tavazzi B., Eikelenboom J., Keir G., Belli A., Giovannoni G., Di Pietro V., Polman C., D'Urso S., Vagnozzi R., Uitdehaag B., and Lazzarino G. Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin. Biochem. (2009)
168. Bredt D.S., Hwang P.M., Glatt C.E., Lowenstein C., Reed R.R., and Snyder S.H. Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351 (1991) 714-718
169. Lowenstein C.J., and Snyder S.H. Nitric oxide, a novel biologic messenger. Cell 70 (1992) 705-707
170. Brosnan C.F., Battistini L., Raine C.S., Dickson D.W., Casadevall A., and Lee S.C. Reactive nitrogen intermediates in human neuropathology: an overview. Dev. Neurosci. 16 (1994) 152-161
171. Bo L., Dawson T.M., Wesselingh S., Mork S., Choi S., Kong P.A., Hanley D., and Trapp B.D. Induction of nitric oxide synthase in demyelinating regions of multiple sclerosis brains. Ann. Neurol. 36 (1994) 778-786
172. Kieseier B.C., Wiendl H., Leussink V.I., and Stuve O. Immunomodulatory treatment strategies in multiple sclerosis. J. Neurol. 255 Suppl. 6 (2008) 15-21
173. Meuth S.G., Kleinschnitz C., and Wiendl H. Recent clinical trials and future therapies. J. Neurol. 255 Suppl. 6 (2008) 93-96
174. Namaka M., Turcotte D., Leong C., Grossberndt A., and Klassen D. Multiple sclerosis: etiology and treatment strategies. Consult. Pharm. 23 (2008) 886-896
175. Costello F., Stuve O., Weber M.S., Zamvil S.S., and Frohman E. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice. Curr. Opin. Neurol. 20 (2007) 281-285
176. Minagar A., Alexander J.S., Schwendimann R.N., Kelley R.E., Gonzalez-Toledo E., Jimenez J.J., Mauro L., Jy W., and Smith S.J. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch. Neurol. 65 (2008) 199-204
177. Wegmann K.W., Wagner C.R., Whitham R.H., and Hinrichs D.J. Synthetic peptide dendrimers block the development and expression of experimental allergic encephalomyelitis. J. Immunol. 181 (2008) 3301-3309
178. Olsen S.A. A review of complementary and alternative medicine (CAM) by people with multiple sclerosis. Occup. Ther. Int. 16 (2009) 57-70
179. Murray T.J. Complementary and alternative medicine for MS. Int. MS J. 13 (2006) 3
180. Yadav V., and Bourdette D. Complementary and alternative medicine: is there a role in multiple sclerosis?. Curr. Neurol. Neurosci. Rep. 6 (2006) 259-267
181. Zhou L., Fan Y.P., and Ye M. Study on immunological pathogenesis of 59 patients with multiple sclerosis of different TCM syndrome types. Zhongguo Zhong Xi Yi Jie He Za Zhi 27 (2007) 599-601
182. Tafreshi A.P., Ahmadi A., Ghaffarpur M., Mostafavi H., Rezaeizadeh H., Minaie B., Faghihzadeh S., and Naseri M. An Iranian herbal-marine medicine, MS14, ameliorates experimental allergic encephalomyelitis. Phytother. Res. 22 (2008) 1083-1086
183. Stangel M. Neuroprotection and neuroregeneration in multiple sclerosis. J. Neurol. 255 Suppl. 6 (2008) 77-81
184. He Z., and Koprivica V. The Nogo signaling pathway for regeneration block. Annu. Rev. Neurosci. 27 (2004) 341-368
185. Cui Q. Actions of neurotrophic factors and their signaling pathways in neuronal survival and axonal regeneration. Mol. Neurobiol. 33 (2006) 155-179
186. Yiu G., and He Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 7 (2006) 617-627
187. Scott L.J., and Figgitt D.P. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18 (2004) 379-396
188. Wang Y., Perchellet E.M., Ward M.M., Lou K., Hua D.H., and Perchellet J.P. Rapid collapse of mitochondrial transmembrane potential in HL-60 cells and isolated mitochondria treated with anti-tumor 1,4-anthracenediones. Anticancer Drugs 16 (2005) 953-967
189. Druzhyna N.M., Wilson G.L., and LeDoux S.P. Mitochondrial DNA repair in aging and disease. Mech. Ageing Dev. 129 (2008) 383-390
190. LeDoux S.P., Druzhyna N.M., Hollensworth S.B., Harrison J.F., and Wilson G.L. Mitochondrial DNA repair: a critical player in the response of cells of the CNS to genotoxic insults. Neuroscience 145 (2007) 1249-1259
191. Koczor C.A., Snyder J.W., Shokolenko I.N., Dobson A.W., Wilson G.L., and Ledoux S.P. Targeting repair proteins to the mitochondria of mammalian cells through stable transfection, transient transfection, viral transduction, and TAT-mediated protein transduction. Methods Mol. Biol. 554 (2009) 233-249
192. Garthwaite G., Goodwin D.A., Batchelor A.M., Leeming K., and Garthwaite J. Nitric oxide toxicity in CNS white matter: an in vitro study using rat optic nerve. Neuroscience 109 (2002) 145-155
193. Black J.A., Liu S., Hains B.C., Saab C.Y., and Waxman S.G. Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE. Brain 129 (2006) 3196-3208
194. Waxman S.G. Axonal conduction and injury in multiple sclerosis: the role of sodium channels. Nat. Rev. Neurosci. 7 (2006) 932-941
195. Black J.A., and Waxman S.G. Phenytoin protects central axons in experimental autoimmune encephalomyelitis. J. Neurol. Sci. 274 (2008) 57-63
196. Webster H.D. Growth factors and myelin regeneration in multiple sclerosis. Mult. Scler. 3 (1997) 113-120
197. Althaus H.H. Remyelination in multiple sclerosis: a new role for neurotrophins?. Prog. Brain Res. 146 (2004) 415-432
198. Linker R.A., Maurer M., Gaupp S., Martini R., Holtmann B., Giess R., Rieckmann P., Lassmann H., Toyka K.V., Sendtner M., and Gold R. CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat. Med. 8 (2002) 620-624
199. Lu Z., Hu X., Zhu C., Wang D., Zheng X., and Liu Q. Overexpression of CNTF in mesenchymal stem cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J. Neuroimmunol. 206 (2009) 58-69
200. Jakovcevski I., Filipovic R., Mo Z., Rakic S., and Zecevic N. Oligodendrocyte development and the onset of myelination in the human fetal brain. Front. Neuroanat. 3 (2009) 5
201. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., Wong W.M., Wang L., Su H., Chu T.H., Guo J., Zhang W., So K.F., Pepinsky B., Shao Z., Graff C., Garber E., Jung V., Wu E.X., and Wu W. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 13 (2007) 1228-1233
202. Mi S., Miller R.H., Tang W., Lee X., Hu B., Wu W., Zhang Y., Shields C.B., Zhang Y., Miklasz S., Shea D., Mason J., Franklin R.J., Ji B., Shao Z., Chedotal A., Bernard F., Roulois A., Xu J., Jung V., and Pepinsky B. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann. Neurol. 65 (2009) 304-315
203. Carlson N.G., and Rose J.W. Antioxidants in multiple sclerosis: do they have a role in therapy?. CNS Drugs 20 (2006) 433-441
204. Mirshafiey A., and Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 31 (2009) 13-29
205. Schreibelt G., Musters R.J., Reijerkerk A., de Groot L.R., van der Pol S.M., Hendrikx E.M., Dopp E.D., Dijkstra C.D., Drukarch B., and de Vries H.E. Lipoic acid affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J. Immunol. 177 (2006) 2630-2637
206. Mao P., Ardeshiri A., Jacks R., Yang S., Hurn P.D., and Alkayed N.J. Mitochondrial mechanism of neuroprotection by CART. Eur. J. Neurosci. 26 (2007) 624-632
207. Mao P., and Jacks R. Transcriptional activity by cocaine-amphetamine-regulated transcript. Mol. Psychiatry 12 (2007) 223-224
208. Wu B., Hu S., Yang M., Pan H., and Zhu S. CART peptide promotes the survival of hippocampal neurons by upregulating brain-derived neurotrophic factor. Biochem. Biophys. Res. Commun. 347 (2006) 656-661
209. Johnson S.K., Diamond B.J., Rausch S., Kaufman M., Shiflett S.C., and Graves L. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial. Explore (NY) 2 (2006) 19-24